Cardiac Marker

• To confirm the diagnose of a cardiac infarction, it is necessary to get information about the type and diffusion of the affected myocardial area.
• In addition to realize the symptoms, notes from
• a cardiogram (50-60% detection rate) as well as biomarkers are used to get a exact diagnose and to decide next steps.
• Currently used cardiac markers (e.g. Troponin T, CK-MB, Myoglobin) either need about 3 to 4 hours (time after chest pain onset) to provide a diagnosis or are not heart-specific.

DIACORDON^TM - GPBB rapid test provides the specific information you require, within the first hour after the chest pain onset started!

DIACORDON^TM Point of Care Test by DIAGENICS:

DIACORDON^TM uses the new biomarker GPBB (the enzyme glykogenphosphorylase isoenzym BB).

GPBB shows a very high and early specificity and sensitivity in case of a acute myocardial infarct in comparison to Troponin T, CK-MB or Myoglobin (already one hour after first cardiac pain).

GPBB is an ischemic marker - the lack of oxygen during a myocardial ischemia activates the GPBB. Therefore GPBB is heart-specific and will not be activated due to an injection, stress or damage of the skeletal muscle.

In practice - What does that mean for you?

• The DIACORDON^TM Point of Care Test can be performed easily and quickly using whole blood, plasma or serum. The sample together with a running buffer is added to the sample port and the mixture migrates on the membrane. A result is given within 15 minutes. In addition we offer you the laboratory test DIACORDON^TM ELISA.
• DIACORDON^TM GPBB is an ischemic marker. Due to its early and high sensitivity to myocardial oxygen deficiencies, GPBB is a reliable marker for the early diagnosis of myocardial infarction, earlier than the currently used markers.
• Before the death of heart muscles cells occurs the early and reliable diagnosis allows you to immediately initiate treatments aimed at rescuing the cardiac tissue and survival of your patients - even in the ambulance
• By this earlier, accurate diagnosis correct treatment for your patients and therefore a reduction of unspecific diagnoses - consequently you lower corresponding risks for your patients and also the costs for your hospital and healthcare systems.
• You can reduce the patients´ hospital stays or dismiss them more earlier if not even immediately. Saving consequential charges (heart failure, disability) are also possible.
• In the cardiac area, you get an optimal surgical management by the early detection of myocardial ischemia and the possibility of rapid detection of re-infarction. Coupled with this are optimized results as well as time and cost savings.

Diagnosis of ACS - earlier, faster more reliable with DIACORDON^TM

Description
Most countries face high and increasing rates of cardiovascular disease. It causes the highest costs for the health care systems in Germany. The most common causes of death within the area of cardiovascular disease are angina pectoris and the myocardial infarction. To confirm the diagnose of a cardiac infarction, it is necessary to get information about the type and diffusion of the affected myocardial area. In addition to realize the symptoms, notes from a cardiogram (50-60% detection rate) as well as biomarkers are used to get a exact diagnose and to decide next steps. Currently used cardiac markers (e.g. Troponin T, CK-MB, Myoglobin) either need about 3 to 4 hours (time after chest pain onset) to provide a diagnosis or are not heart-specific. Thus hospitals treat more suspicious cases than necessary as an inpatient. In other cases patients arise consequences out of treatment delay.

Innovation
DIACORDON^TM uses the new biomarker GPBB (the enzyme glycogenphosphorylase isoenzym BB). GPBB shows a very high and early specificity and sensitivity in case of a acute myocardial infarct in comparison to Troponin T, CK-MB or Myoglobin (already one hour after first cardiac pain). DIACORDON^TM also allows the diagnosis of angina pectoris and stenosis. With DIACORDON^TM a rapid diagnosis can be achieved before the death of heart muscle cells occurs.

Cost Savings
Economization arise due to the facility of early therapy of an acute myocardial infarct. The storage period of patients in hospital becomes 10% fewer compared with the present standard marker Troponin. Moreover, savings grow out of possible invasive checkups of about 30% of patients having suspicion of an heart infarct, which was not approved by new diagnostic of Biomarkers.

Cost-/Use Analyze

The cost and use effect of Diacordon is shown with a contrast of Troponin and Diacordon and the duration a patient has to stay in hospital after get tested with one of the markers. We act on the assumption that using Diacordon can reduce the stay in hospital for 10%.

Compared with the cardiac catheter examination, Diacordon shows a much higher economization, too. In Germany, there are about 800000 examinations like this per year. This estimate can be reduced for about 30% if safe diagnosis is made in advance1. Just the reduction of operations results as additional economization of 950 million euros.

^{1 See study of D.G. Fischer, F. Fuchs, R. Bachus: A not invasive method in cardiology. Is it a really expansive procedure? (Hrsg. Electromedica 70(2002) book 1, page 31). The authors act on the assumption that about 60% of operations can be reduced. This leads to an economization of 1,9 billions euros. As basic in this study, a close account of the half of this assumption was taken}